Ustekinumab as Salvage Therapy in a Patient with Acute Severe Ulcerative Colitis

Coşkun, Özge; Özen Alahdab, Yeşim; Atuğ, Özlen; Kani, Haluk Tarık

doi:10.14744/Jenterocolitis.2025.00529

Özge Coşkun¹ ,

Yeşim Özen Alahdab² ,

Özlen Atuğ² ,

Haluk Tarık Kani²

¹Department of Internal Medicine, School of Medicine, Marmara University, Istanbul, Turkiye
²Department of Gastroenterology, School of Medicine, Marmara University, Istanbul, Turkiye

Journal of Enterocolitis - DOI: 10.14744/Jenterocolitis.2025.00529

Abstract

A patient with left-sided ulcerative colitis presented with acute severe ulcerative colitis (ASUC) after experiencing inadequate responses to two advanced therapies. The patient had previously been treated with vedolizumab for 14 months before being switched to infliximab due to secondary unresponsiveness. Ustekinumab was initiated as a rescue therapy for ASUC, leading to clinical improvement. At the six-month follow-up, the patient remained in remission.

Keywords: Salvage therapy, ulcerative colitis, ustekinumab